Sign In
Buy CDAK
$0.0570
+0 (+0%)
At Close: Jul 03, 2023
Codiak's Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy
09:00am, Thursday, 21'st Jan 2021
– New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties –
– exoIL-12 resulted in no local or systemic treatment-related adverse events –
Codiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference
07:30am, Monday, 23'rd Nov 2020
CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class
Codiak BioSciences Reports Third Quarter 2020 Financial Results and Operational Progress
04:05pm, Thursday, 19'th Nov 2020
– Human clinical testing now underway with Codiak's first two candidates, exoIL-12™ and exoSTING™ –
– exoIL-12™ demonstrates tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo –
